Citations

Clear

3485 citation(s) found for "Sy, Sarah".

BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and
Arbour, Kathryn C. , George, Ben , Henry, Jason T. , Leventakos, Konstantinos , Ahnert, Jordi Rodon, Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Wozniak, A., Chin, Curtis D., Mazzei, Antonella , Hu, Zheyi , Simpson, Tyler R., Dickinson, Adam , Jänne, Pasi A. , Ahnert, Jordi Rodon, Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Chin, Curtis

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3011-3011

10.1200/jco.2025.43.16_suppl.3011 Get It

3011 Background: BMS-986504 selectively binds to the PRMT5-MTA complex, which represents a synthetic lethal target in MTAP -del cancer cells, while sparing MTAP– wild-type cells. In the first-in-human phase 1/2 CA240-0007 study in advanced, unresectable or metastatic solid tumors with homozygous MTAP -del, BMS-986504 was found to be well tolerated and demonstrated antitumor activity in multiple tumors. Here, we report clinical results and the first PK and PD analyses of BMS-986504 from the dose escalation and expansion phases of CA240-0007. Methods: Pts with measurable/evaluable disease and no available treatment (Tx) with curative intent were enrolled; 7 doses were evaluated (50 to 800 mg) in dose escalation. Objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to response (TTR), safety, PK, PD, including plasma SDMA were assessed. Results: As of 2 Dec 24, 152 heavily pretreated pts were enrolled across all doses: NSCLC (n = 34), PDAC (n = 41), cholangiocarcinoma (n = 12), and mesothelioma (n = 12) were the most common tumor types. With a median f/u of 9.0 mo (95% CI 7.6–9.9), continued durable antitumor activity and deepening tumor regression were seen across tumor types and doses (ORR = 23%, DCR = 70%, median DOR = 10.5 mo, TTR = 4.6 mo). No new safety signals were identified. Most Tx-related adverse events (TRAEs) were grade (Gr) 1 or 2; 13% had Gr ≥ 3 TRAEs (Gr 3 = 12%, Gr 4 = < 1%, Gr 5 = 0). Doses from 50 to 600 mg QD were assessed for PK/PD. The AUC (0-24) after multiple doses was approximately dose proportional at 200 to 600 mg, and the terminal t 1/2 after a single dose was approximately 24 h (table). There were dose-dependent reductions in predicted plasma SDMA, with the 400 and 600 mg doses approaching the plateau. Conclusions: With longer f/u, BMS-986504 continued to show increasingly durable antitumor activity. BMS-986504 demonstrated a favorable PK/PD profile, supporting QD dosing at 400 and 600 mg. These results support further investigation of BMS-986504 at 400 and 600 mg QD as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP -del. Clinical trial information: NCT05245500 . PK and PD. 50 mg QD 100 mg QD 200 mg QD 400 mg QD 600 mg QD PK after multiple doses t max a (min–max), h 2.0 (2.0–4.0)n = 3 2.0 (1.0–2.0)n = 3 2.0 (0.5–6.0)n = 8 2.0 (0.5–4.0)n = 10 2.0 (1.0–6.0)n = 10 C max , b ng/mL 107n = 3 377n = 3 685n = 8 1240n = 10 2110n = 10 AUC (0-24) , b h∙ng/mL 948 n = 3 3060 n = 3 7150 n = 7 11,800n = 10 26,700n = 9 AUC (0-24) , b,c h∙ng/mL/mg 19.0n = 3 30.6n = 3 35.8n = 7 29.5n = 10 44.6n = 9 Terminal t 1/2 after single dose, d h 21.7 n = 1 80.7 n = 1 21.5 n = 14 21.7 n = 14 24.1 n = 1 PD Translational exposure targets (C avgss ), X 0.08 0.21 0.5 1.1 1.7 Predicted plasma SDMA reduction, a % (90% PI) 30.0 (23.2–37.8) 38.8 (27.1–47.5) 48.3 (42.0–53.0) 55.0 (50.7–57.6) 57.4 (54.3–59.0) a Median. b Geometric mean. c Dose-normalized. d Arithmetic mean.
New horizons in advancing lifestyle medicine for older adults utilizing a transdisciplinary approach: gaps and opportunities
Lassell, Rebecca , Pritchard, Kevin , Baehr, Laura , Ceïde, Mirnova E. , Jayakody, Oshadi , Lieber, Sarah B. , Loewenthal, Julia , Na, Annalisa , Makris, Una E. , Sherman, Andrea, Wagle, Kamal C. , Andonian, Brian J. , Lassell, Rebecca K F , Sheshadri, Anoop , Makris, Una E , Chatterjee, Sudeshna A, Colón-Semenza, Cristina , Mosher, Christopher L. , Myasoedova, Elena , Wingood, Mariana

Mayo Clinic

Age and Ageing | May 28, 2025 | Volume: 54 | Issue: 6 | Pages: No page available

10.1093/ageing/afaf159 | PMID 40511981 Get It

Abstract Nearly half of premature deaths can be prevented with healthy lifestyle behaviours. However, most older adults do not adhere to established guidelines to promote a healthy lifestyle. We propose a tailored framework of lifestyle medicine that acknowledges the complex contexts and care needs of older adults. The proposed framework of lifestyle medicine for older adults integrates their lived experiences (e.g. social determinants of health, built environment), the 5 M framework of geriatric medicine (i.e. Mind, Mobility, Medications, Multicomplexity, Matters Most) and the six pillars of lifestyle medicine (i.e. nutrition/diet, physical activity/exercise, restorative sleep, stress management, avoidance of risky substances, positive social connections) through a novel transdisciplinary approach. Guided by the updated framework, key gaps and opportunities are presented to advance lifestyle medicine practice, research and policy with the goal of promoting sustained behaviour change and improving the healthspan of older adults.
Deep learning on brief interictal intracranial recordings can accurately characterize seizure onset zones
Sundrani, Sameer , Doss, Derek J. , Makhoul, Ghassan S. , Lerma, Bruno Hidalgo Monroy , Reda, Anas, Cavender, Addison C. , Liao, Emily, Bick, Sarah K. , Morgan, Victoria L. , Englot, Dario J. , Doss, Derek J , Hidalgo Monroy Lerma, Bruno , Morgan, Victoria L , Englot, Dario J , Bick, Sarah K , Johnson, Graham W. , Rogers, Baxter P. , Williams Roberson, Shawniqua

Mayo Clinic

Epilepsia | May 27, 2025 | Volume: 66 | Issue: 9 | Pages: 3180-3192

10.1111/epi.18478 | PMID 40423629 Get It

AbstractObjectiveEpilepsy is a debilitating disorder affecting more than 50 million people worldwide, and one third of patients continue to have seizures despite maximal medical management. If patients' seizures localize to a discrete brain region, termed a seizure onset zone, resection may be curative. Localization is often confirmed with stereotactic electroencephalography; however, this may require patients to stay in the hospital for weeks to capture spontaneous seizures. Automated localization of seizure onset zones could therefore improve presurgical evaluation and decrease morbidity.MethodsUsing more than 1 000 000 interictal stereotactic electroencephalography segments collected from 78 patients, we performed five‐fold cross‐validation and testing on a multichannel, multiscale, one‐dimensional convolutional neural network to classify seizure onset zones.ResultsAcross held‐out test sets, our models achieved a seizure onset zone classification sensitivity of .702 (95% confidence interval [CI] = .549–.805), specificity of .741 (95% CI = .652–.835), and accuracy of .738 (95% CI = .687–.795), which was significantly better than models trained on random labels. The models performed well across the entire brain, with top five region performance demonstrating accuracies between 70.0% and 88.4%. When split by outcomes, the models performed significantly better on patients with favorable Engel outcomes after resection or who were responsive neurostimulation responders. Finally, SHAP (Shapley Additive Explanation) value analysis on median‐normalized input data assigned consistently high feature importance to interictal spikes and large deflections, whereas similar analyses on histogram‐equalized data revealed differences in feature importance assignments to low‐amplitude segments.SignificanceThis work serves as evidence that deep learning on brief interictal intracranial data can classify seizure onset zones across the brain. Furthermore, our findings corroborate current understandings of interictal epileptiform discharges and may help uncover novel interictal morphologies. Clinical application of our models may reduce dependence on recorded seizures for localization and shorten presurgical evaluation time for drug‐resistant epilepsy patients, reducing patient morbidity and hospital costs.
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
Hawkes, Will, Woodward, Gary , Hamza, Izhan, Desai, Viral , Barrett‐O’Keefe, Zachary , Grogan, Martha, Davison, Halley, Maurer, Mathew S. , Helmke, Stephen , Scherrer‐Crosbie, Marielle , Soltani, Marwa , Goyal, Akash , Zaręba, Karolina M. , Cheng, Richard K. , Vieira, Marcelo Luiz Campos , Elissamburu, Pablo , Ronderos, Ricardo , Prado, Aldo , Sarswat, Nitasha , Addetia, Karima , Ruberg, Frederick L. , Randazzo, Michael , Al-Roub, Nora , Kidd, Liam, Lang, Roberto M. , Pellikka, Patricia A. , Barrett-O'Keefe, Zachary, Scott, Christopher , Davison, Halley N, Cheng, Richard , Kirkpatrick, James N , Koutroumpakis, Efstratios , Deswal, Anita M , Pursnani, Amit , Pellikka, Patricia A , Slivnick, Jeremy A. , Hawkes, Will, OLIVEIRA, JORGE COELHO , Akerman, Ashley, Gómez, Alberto , Grogan, Martha , Dispenzieri, Angela , Scott, Christopher G. , Cotella, Juan Ignacio , Maurer, Mathew S , Kitano, Tetsuji , Takeuchi, Masaaki , Hotta, Viviane Tiemi , Patel, Amit R. , Asch, Federico M. , O’Driscoll, Jamie M. , Strom, Jordan B. , Kidd, Liam, Cuddy, Sarah A. M. , Upton, Ross

Mayo Clinic

European Heart Journal | May 26, 2025 | Volume: 46 | Issue: 40 | Pages: 4090-4101

10.1093/eurheartj/ehaf387 | PMID 40631729 Get It

Abstract Background and Aims Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed. Methods Utilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness. Results Cardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores. Conclusions This AI screening model—using only an apical four-chamber view—effectively differentiated CA from other causes of increased left ventricular wall thickness.
Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease
Hassenstab, Jason , Sung, Yun Ju, Daniels, Alisha , Xiong, Chengjie , Perrin, Richard J. , Day, Gregory S. , Supnet, Charlene , Berman, Sarah , Chhatwal, Jasmeer P. , Huey, Edward D. , Ryan, Natalie S. , Laske, Christoph , Xiong, Chengjie , Roh, Jee Hoon , Lopera, Francisco , team, For DIAN study, McDade, Eric M , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Roh, Jee Hoon , Supnet-Bell, Charlene , Berman, Sarah , Liu, Haiyan , Bui, Quoc Van Phu , Gordon, Brian A. , Benzinger, Tammie L.S. , Timsina, Jigyasha , Sung, Yun Ju, Karch, Celeste M. , Renton, Alan , Morris, John C. , Ibanez, Laura , Llibre‐Guerra, Jorge J. , Xu, Xiong, Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Jucker, Mathias , Vöglein, Jonathan , Lopera, Francisco Javier , Bateman, Randall J. , Cruchaga, Carlos , McDade, Eric , team, For DIAN study

Mayo Clinic

Alzheimer's & Dementia | May 24, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70243 | PMID 40411302 Get It

AbstractINTRODUCTIONThis study investigated the role of the ubiquitin–proteasome system (UPS) in dominantly inherited Alzheimer's disease (DIAD) by examining cerebrospinal fluid (CSF) levels of UPS proteins.METHODThe SOMAscan assay was used to detect changes in UPS proteins in mutation carriers (MCs) relative to disease progression; imaging and CSF biomarkers of amyloid, tau, and neurodegeneration measures; and Clinical Dementia Rating scale.RESULTSSubtle increases in specific ubiquitin enzymes were detected in MCs up to two decades before symptom onset, with more pronounced elevations in UPS‐activating enzymes near symptom onset. Significant correlations were found between UPS proteins and Alzheimer's disease (AD) biomarkers, especially between autophagy markers and late‐stage tau biomarkers, microglia, and axonal degeneration.DISCUSSIONThe rise in UPS proteins alongside tau‐related markers suggests UPS involvement in tau neurofibrillary tangles. Elevated CSF UPS proteins in DIAD MCs may serve as indicators of disease progression, and may support the UPS as a therapeutic target in AD.Highlights This study investigates the ubiquitin‐proteasome system (UPS) in Dominantly Inherited Alzheimer's Disease (DIAD), highlighting early molecular changes linked to disease progression. Using SOMAscan proteomics, we identified significant UPS protein alterations in cerebrospinal fluid of mutation carriers, notably up to 20 years before clinical symptom onset. Correlations between UPS protein levels and Alzheimer's biomarkers, particularly tau and neurodegeneration markers, suggest a strong association between UPS dysregulation and tau pathology in DIAD. Dynamic UPS changes align with A/T biological staging: UPS proteins were shown to increase across Aβ/tau (A/T) groups, with largest increases in the A+/T+ group, reinforcing their role in late‐stage tau pathology and disease progression. These findings underscore the potential of UPS proteins as early biomarkers for Alzheimer's disease progression and as novel therapeutic targets, especially in tau‐pathology‐driven neurodegeneration. This work contributes to understanding AD pathogenesis, by emphasizing the importance of protein quality control systems and by offering avenues for future biomarker discovery and therapeutic development in Alzheimer's disease.
Outcomes of medical and surgical management in infectious intracranial aneurysms: a multicenter cohort analysis
Alawieh, Ali , Zohdy, Youssef M. , Koo, Andrew B. , Saad, Hassan , Baba, Bachar El , Newman, Sarah, Grossberg, Jonathan A , Matouk, Charles , Cawley, C. Michael, Reisner, Andrew , Perez‐Vega, Carlos , Burkhardt, Jan‐Karl , Salem, Mohamed M , Jabbour, Pascal , Naamani, Kareem El, Gooch, M Reid, Starke, Robert M., Abdelsalam, Ahmed , Lu, Victor M , Chalhoub, Reda , Spiotta, Alejandro M , Alawieh, Ali M , Zohdy, Youssef M , Koo, Andrew B , El Baba, Bachar , Grossberg, Jonathan A , Matouk, Charles , Fox, W Christopher , Perez-Vega, Carlos , Jabbour, Pascal , Levitt, Michael R , Chalhoub, Reda M , Spiotta, Alejandro M , Howard, Brian M , Burkhardt, Jan‐Karl , Dimisko, Laurie , Pradilla, Gustavo , Naamani, Kareem El , Schmidt, Richard F. , Gooch, Michael Reid , Abdelsalam, Ahmed, Levitt, Michael R. , Kobeissy, Firas , Barrow, Daniel L.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 23, 2025 | Volume: 18 | Issue: 4 | Pages: 1079-1086

10.1136/jnis-2025-023421 | PMID 40409986 Get It

Introduction Infectious intracranial aneurysms (IIAs) are rare but serious complications of systemic infections, particularly infective endocarditis. These aneurysms are prone to rupture, leading to significant morbidity and mortality. Management strategies lack consensus due to the rarity of the condition and reliance on small case series. This study examines the clinical management of IIAs using data from a large multicenter cohort. Methods A retrospective registry-based cohort study was conducted across 11 tertiary care centers in the USA between 2018 and 2023. Patients with IIAs were identified based on clinical and radiographic criteria. The primary outcome was treatment failure defined as persistence, growth, or rupture of the aneurysm. Secondary outcomes were mortality and the modified Rankin Scale (mRS) score at 90 days and 1 year. Multivariate logistic regressions were used to identify outcome predictors. Results A total of 104 patients with 166 aneurysms were included, with a median age of 43 years. Medical management was successful in 56% of cases, with failure often within 18 days of initiation. Predictors of failure included younger age, larger aneurysm size, and rupture at presentation. Surgical and endovascular interventions achieved higher success rates with better outcomes. At 90 days, 57% of patients achieved functional independence (mRS 0–2), while the mortality rate was 24%. Conclusion This study highlights the limitations of medical management for IIAs and underscores the need for early surgical or endovascular intervention in high-risk patients. Outcome predictors aid clinical decision-making, optimizing patient management. Further research is needed to standardize management guidelines for IIAs.
Safety in a hybrid hospital‐at‐home program versus traditional inpatient care: A pragmatic randomized controlled trial
Maniaci, Michael J. , Sangaralingham, Lindsey R. , Behnken, Emma , Hart, Melissa S., Inselman, Shealeigh A., Nelson, Chad R. , Gothot, Rachel A., Smith, Y.R., Oloyede, Sey V. , Gifford, Sarah L., Taylor, Josh D., Dunn, Ajani N., Dowdy, Sean C. , Bosch, Wendelyn , Cowart, Jennifer B. , Behnken, Emma M, Paulson, Margaret, Nelson, Chad R , Chang, Yu‐Hui H., Hanson, Kristine T. , Larson Smith, Yvonne M, Dunlay, Shannon M. , Habermann, Elizabeth , Cowart, Jennifer B , Yao, Xiaoxi , Maniaci, Michael J , Inselman, Shealeigh A., Paulson, Margaret R. , Chang, Yu‐Hui , Smith, Yvonne M. Larson, Taylor, Josh D., Habermann, Elizabeth B. , Yao, Xiaoxi

Mayo Clinic

Journal of Hospital Medicine | May 22, 2025 | Volume: 20 | Issue: 11 | Pages: 1174-1184

10.1002/jhm.70076 | PMID 40400147 Get It

Abstract Background Hospital‐at‐home programs (HaH) in the United States have evolved to include a virtual‐hybrid delivery model, where all physician encounters are virtual and partnered with a home care team. Objective To examine whether a virtual hybrid HaH program enabled by technology has similar clinical outcomes to traditional brick‐and‐mortar (B&M) hospital care. Methods We conducted a pragmatic trial at three hospitals, randomizing 1150 acutely ill patients requiring hospital care between July 10, 2023, and October 31, 2023 one‐to‐one into two groups: intervention (HaH) and control (B&M). The primary analysis was an intention‐to‐treat non‐inferiority analysis of the primary outcome, which was a composite of 30‐day all‐cause mortality and unplanned readmissions. Secondary outcomes included 30‐day readmission, all‐cause mortality, and patient experience. Results The mean age was 67.8 (standard deviation [SD] 16.3) years, and 52.2% were female. The primary outcome occurred in 99 (17.3%) HaH patients and 114 (19.8%) B&M patients (odds ratio [OR] 0.85, 95% confidence interval [CI] 0.63–1.14, p = .28), meeting the non‐inferiority criterion. Thirty‐day unplanned readmission occurred in 84 (14.7%) HaH patients and 101 (17.5%) B&M patients (OR 0.81, 95% CI 0.59–1.11, p = .19). Thirty‐day all‐cause mortality occurred in 25 (4.4%) HaH patients and 19 (3.3%) B&M patients (OR 1.34, 95% CI 0.73–2.46, p = .35). No HaH patients died while receiving their hospital care at home. HaH program was associated with a higher likelihood of patients reporting feeling extremely comfortable or very comfortable (84.4% HaH; 60.9% B&M, p = .001). Conclusion A hybrid HaH model is a safe and comfortable alternative to traditional B&M hospital care.
The Role and Performance of Postoperative Imaging After Repair of a Perforated Peptic Ulcer
Strajina, Veljko , Lund, Sarah , Zhu, Rebecca, Stephens, Daniel , Zietlow, John , Heller, Stephanie F. , Turay, David, Mahmoud, Khalid , Harmsen, William S. , Ahmed, Amin Mohamed , Lund, Sarah B, Zietlow, John M, Mahmoud, Khalid H., Mohamed Ahmed, Amin, Khandelwal, Ashish , Stephens, Daniel

Mayo Clinic

World Journal of Surgery | May 21, 2025 | Volume: 49 | Issue: 8 | Pages: 2116-2122

10.1002/wjs.12622 | PMID 40399251 Get It

ABSTRACTBackgroundWe aimed to determine the performance of postoperative computed tomography (CT) and upper gastrointestinal series (UGI) in patients who underwent surgery for a perforated peptic ulcer and to assess the yield of routine postoperative studies.MethodsRetrospective, single‐institution, chart‐review study of patients who underwent a repair of a perforated gastric or duodenal ulcer between August 2004 and September 2021 at Mayo Clinic, Rochester, Minnesota.ResultsWe identified a total of 240 patients, 28 (12%) were found to have leaks. When any of the four findings (extraluminal gas or fluid collection adjacent to the repair, worsening pneumoperitoneum, or enteral contrast extravasation) was present on postoperative CT scan (n = 116) it had sensitivity of 76% (95% CI 53%–90%), with a specificity of 90% (95% CI 84%–91%). Upper gastrointestinal series (UGI, n = 150) showed a sensitivity of 57% (95% CI 25%–84%) and a specificity of 99% (95% CI 96%–100%). UGI demonstrated higher specificity compared to CT (p < 0.01); there was no significant difference in sensitivity (p = 0.34). The findings from CT scans led to changes in management for a significantly greater number of patients compared to UGI (20% vs. 4%, p < 0.01). The diagnostic yield for leak identification was 3% for routine postoperative CT (n = 63) and 2% for routine UGI studies (n = 141).ConclusionsPostoperative CT is more likely to change management in patients who underwent repair of a perforated peptic ulcer compared to postoperative upper gastrointestinal series. The yield of routine postoperative studies is low, and their benefit is uncertain.
0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study
Schneider, Logan , Ruoff, Chad , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Cairns, Alyssa , Ruoff, Chad M , Plante, David T. , Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A360-A360

10.1093/sleep/zsaf090.0831 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on daytime and nighttime symptoms in participants with narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia. Data presented are from the narcolepsy cohort. Methods DUET included a screening period (with 2-week washout for current oxybate users), 8-day baseline (BL) period, 2- to 8-week LXB titration period, 2-week stable-dose period, 8-day end-of treatment (EOT) period, and 2-week safety follow-up. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Key secondary endpoints for the narcolepsy cohort included change in polysomnography parameters: total shifts from deeper to lighter sleep stages, stage N3 sleep duration (minutes), and number of awakenings. Additional endpoints included Patient Global Impression of Change (PGIc)–overall narcolepsy disease. Primary and key secondary endpoints were controlled for multiplicity with sequential testing; other P-values are considered nominal. Results Fifty-five narcolepsy participants enrolled and were dosed with LXB (NT1, n=26; NT2, n=29); 13 transferred to another cohort and 34 were completers (NT1, n=16; NT2, n=18). Enrolled participants were mostly female (72.7%) and White (80.0%); mean (SD) age was 33.4 (12.9) years (NT1=34.6 [12.6]; NT2=32.4 [13.2]). For completers, least-squares mean (LSM) (SE) changes in ESS score were −7.7 (0.9), P&lt;.0001, overall; NT1=−6.5 (1.4), P&lt;.0001; NT2=−8.8 (1.3), P&lt;.0001. Compared with BL, sleep architecture at EOT showed fewer deeper to lighter sleep stage shifts (LSM [SE]: −13.1 [2.9], P&lt;.0001, overall; NT1=−13.9 [4.3], P=0.0029; NT2=−12.3 [4.1], P=0.0050); increased stage N3 sleep (minutes) (45.0 [8.8], P&lt;.0001, overall; NT1=49.8 [13.0], P=0.0006; NT2=40.8 [12.3], P=0.0023); and fewer awakenings (−3.2 [0.9], P=0.0015, overall; NT1=−4.1 [1.4], P=0.0056; NT2=−2.3 [1.3], P=0.0771). Most participants (93.3%, n=30; NT1, 86.7%, n=15; NT2, 100%, n=15) reported improvement (very much, much, minimally) in overall narcolepsy disease on PGIc. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion Participants with NT1 and NT2 taking open-label LXB showed improvements in daytime sleepiness (decreased ESS scores) and reduced symptom burden (improved PGIc), which paralleled improvements in sleep architecture and disruption. Support (if any) Jazz Pharmaceuticals
0851 Effectiveness and Safety of Low-Sodium Oxybate in Idiopathic Hypersomnia Participants: Results from the DUET Study
Cairns, Alyssa , Schneider, Logan , Nichols, Deborah A. , Steininger, Teresa L. , Kirby, Melanie, Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Ruoff, Chad , Ruoff, Chad M , Plante, David T. , Fuller, Douglas, Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A369-A369

10.1093/sleep/zsaf090.0851 Get It

Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on daytime and nighttime symptoms, including excessive daytime sleepiness (EDS) and polysomnography in participants with idiopathic hypersomnia (IH) or narcolepsy. Data presented are from the IH cohort. Methods DUET included screening (with 2-week washout for oxybate users), 8-day baseline (BL), 2- to 8-week LXB titration, 2-week stable-dose, 8-day end-of-treatment (EOT), and 2-week safety follow-up periods. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Secondary endpoints for the IH cohort included change in Idiopathic Hypersomnia Severity Scale (IHSS) total score, Patient Global Impression of Change (PGIc)−overall IH disease, PGIc−sleep inertia, and Patient Global Impression of Severity (PGIs)−sleep inertia. Exploratory endpoints included IHSS component scores (daytime functioning, sleep inertia). Primary and key secondary (IHSS total score) endpoints were controlled for multiplicity with sequential testing; all other P-values are considered nominal. Results Forty-six people with IH enrolled and were dosed with LXB; 40 were completers. Enrolled participants were mostly female (80.4%) and White (84.8%), with a mean (SD) age of 38.1 (11.8) years. For completers, BL mean (SD) ESS score and IHSS total score were 16.5 (2.7) and 32.9 (7.1), respectively; least-squares mean (LSM) (SE) changes from BL to EOT were −8.4 (0.7), P&lt;.0001 and −15.5 (1.5), P&lt;.0001. BL mean (SD) IHSS component scores for daytime functioning and sleep inertia were 17.7 (4.2) and 10.7 (3.1), respectively; LSM (SE) changes from BL to EOT were −8.8 (1.0), P&lt;.0001 and −4.8 (0.4), P&lt;.0001. At EOT, most participants reported improvement (very much, much, minimally) on PGIc−overall IH disease (94.6%) and PGIc−sleep inertia (81.1%). At BL, 25.0% of participants reported sleep inertia severity as very mild/mild/not present on PGIs–sleep inertia vs 59.0% at EOT. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion People with IH taking open-label LXB showed improvements in EDS and sleep inertia (decreased ESS and IHSS component scores) and reported reduced multi-symptom burden (decreased IHSS total scores and improved PGIc/PGIs ratings). Support (if any) Jazz Pharmaceuticals